Last Updated : April 27, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort ascending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Trintellix | Vortioxetine | Depression, major depressive disorder | Withdrawn | |||
| Zolinza | vorinostat | Cutaneous T-cell lymphoma | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| VFEND | Voriconazole | Aspergillosis, Invasive | Withdrawn | |||
| VFEND | Voriconazole | Aspergillosis, Invasive | List with clinical criteria and/or conditions | Complete | ||
| VFEND | Voriconazole | Candidemia | List with clinical criteria and/or conditions | Complete | ||
| Luxturna | voretigene neparvovec | Vision loss, inherited retinal dystrophy | Reimburse with clinical criteria and/or conditions | Complete | ||
| Vonvendi | von Willebrand Factor [recombinant] | von Willebrand disease, adults, treatment and perioperative management | Reimburse with clinical criteria and/or conditions | Complete | ||
| Erivedge | Vismodegib | Basal Cell Carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Viibryd | vilazodone | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Verquvo | vericiguat | Heart failure | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 27, 2024